STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%

October 15, 2009
    Million EUR                    2008                 2009          09/08
                            EURm       % Sales    EURm       % Sales  Var.%
    Southern Europe (1)     23.8            70      26            68     9
    Other EU countries (2)   8.6            25    10.3            27    20
    Other markets            1.8             5     1.9             5     8
    SLIT                    26.3            77    30.5            79    16
    SCIT                     6.5            19     6.3            17    (2)
    Other products           1.4             4     1.4             4     0
    Total Q3 sales          34.2           100    38.2           100    12

    Million EUR                    2008                 2009          09/08
                            EURm       % Sales    EURm       % Sales  Var.%
    Southern Europe (1)     88.6            74    96.3            71     9
    Other EU countries (2)  27.2            22    34.4            25    27
    Other markets            5.5             4     5.2             4    (5)
    SLIT                    97.6            81   111.6            82    14
    SCIT                    18.8            15    19.1            14     2
    Other products           4.8             4     5.2             4     7
    Cumulated Sales        121.2           100   135.9           100    12

    (1) Potugal,Spain,France,Italy,Greece; (2) Switzerland included

Sales performance and financial position

Sales grew at a rate equal to that of the first half year, which was 3
points higher than the growth in the 2nd quarter 2009. This dynamic remained
driven, as in the 1st half year, by the markets of Northern Europe (“Other EU
countries”) and the sublingual route, which maintained double digit growth
rates. This performance must be highlighted against the background of an
unfavourable base effect, of strong growth recorded in the 3rd quarter 2008

Organic growth, both in quarterly and cumulative data and restated for
the currency effect was 11%.

Net debt at the end of September 2009 was down by 18% compared to the end
of September 2008.

Significant transactions and events in the quarter

The mutual recognition procedure for Oralair(R) in adult and paediatric
indication (desensitising tablet for grass pollen), continued and should lead
to obtaining a registration in most European markets by the end of 2009.

Following the positive results of the phase III clinical study with
Actair(R) (desensitising tablet for dust mites) in adults, an application for
a phase III clinical study for children in respect of 450 patients was filed
in Europe and the registration strategy for Actair(R) for adults is currently
being defined.

Stallergenes announced on 16 September positive preliminary results for a
phase IIb/III clinical study carried out on allergic rhinitis to birch pollen
using a recombinant allergen as active ingredient. The confirmation phase III
study should be carried out during the 2011 pollen season.

Outlook for current year

The good level of sales to the end of September now leads to guidance of
growth of 10% or slightly greater for 2009. Given this outlook, Stallergenes
expects net profit to be close to that of the previous year. Lastly, the last
quarter will be marked by the publication in December of three important
phase III clinical results on Oralair(R):

    - the US study on adult indication,
    - the 3rd year of a long-term study,
    - the study for the optimisation of protocols.

The preliminary results of a phase III study on Staloral(R) dust mites in
asthma carried out in China will also be published.

About Stallergenes

Stallergenes is a European biopharmaceutical laboratory specialising in
the treatment by desensitisation of allergy-related respiratory conditions,
such as rhino conjunctivitis or allergic asthma. A pioneer and a leader in
desensitisation treatments by sublingual administration, Stallergenes
dedicates 21% (gross) of its sales to its Research and Development
activities, which are primarily directed at developing a new therapeutic
range enabling the provision of desensitisation treatments by sublingual

Stallergenes realised 2008 sales of EUR 171 million, with over 500,000
patients treated with Stallergenes desensitisation products.

    Stallergenes trades on Compartment B of the Euronext
    Paris Stock Exchange and is a component of the SBF 120

    ISIN Code: FR0000065674

    Reuters Code: GEN.PA

    Bloomberg Code: GEN.FP

For further financial information, please visit our website:

SOURCE Stallergenes

Source: newswire

comments powered by Disqus